Eplerenone in chronic heart failure with depressed systolic function

Area of Science:

• Cardiology
• Pharmacology

Background:

• Eplerenone, a selective mineralocorticoid receptor antagonist, is now used for chronic heart failure (CHF) with reduced systolic function.
• Evidence synthesis is needed to clarify its therapeutic role in CHF management.

Purpose of the Study:

• To review current evidence on eplerenone's efficacy and role in treating patients with chronic heart failure.

Main Methods:

• Review of major clinical trials, including EPHESUS (post-MI patients) and EMPHASIS-HF (mild CHF patients).
• Analysis of outcomes such as mortality, cardiovascular death, hospitalization, and adverse events.

Main Results:

• Eplerenone initiated early (<7 days) post-MI reduced all-cause mortality by 15% and CV death/hospitalization by 13%.
• In mild CHF (NYHA class II), eplerenone reduced CV death/HF hospitalization risk by 37% over 21 months.
• Recommended dosage is 25-50mg daily, with monitoring for hyperkalemia and renal issues.

Conclusions:

• Eplerenone is recommended for CHF patients (NYHA class II-IV) similar to those in key trials, when added to standard therapy.
• Its benefit in CHF patients with very mild symptoms and no additional risk factors remains undetermined.